Tag Archives: WVE

Analysts Have Conflicting Sentiments on These Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Hookipa Pharma (NASDAQ: HOOK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Wave Life Sciences (WVE – Research Report) and Hookipa Pharma (HOOK – Research Report). Wave Life Sciences (WVE) RBC Capital analyst Luca Issi maintained a

Leerink Partners Sticks to Their Hold Rating for Wave Life Sciences (WVE)

Leerink Partners analyst Mani Foroohar reiterated a Hold rating on Wave Life Sciences (WVE – Research Report) on March 4 and set a price target of $10.00. The company’s shares closed last Friday at $9.44. According to TipRanks.com, Foroohar is

H.C. Wainwright Initiates a Buy Rating on Wave Life Sciences (WVE)

Wave Life Sciences (WVE – Research Report) received a Buy rating and a $20.00 price target from H.C. Wainwright analyst Andrew Fein today. The company’s shares closed last Monday at $9.21. According to TipRanks.com, Fein is a 5-star analyst with

Mizuho Securities Thinks Wave Life Sciences’ Stock is Going to Recover

In a report issued on June 5, Salim Syed from Mizuho Securities maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with a price target of $21.00. The company’s shares closed last Friday at $9.23, close to

Wave Life Sciences (WVE) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Wave Life Sciences (WVE – Research Report) today and set a price target of $20.00. The company’s shares closed last Monday at $8.02, close to its 52-week low of $7.78.

Wave Life Sciences (WVE) Receives a Hold from Cowen & Co.

Cowen & Co. analyst Yaron Werber maintained a Hold rating on Wave Life Sciences (WVE – Research Report) today. The company’s shares closed last Monday at $17.86, close to its 52-week low of $17.50. According to TipRanks.com, Werber is a